Concurrent Cisplatin-Based Chemoradiation and Adjuvant Hysterectomy for Bulky Stage IB-IIA Cervical Cancer
Chalong Cheewakriangkrai, MD*, Jatupol Srisomboon, MD*, Imjai Chitapanarux, MD**, Prapaporn Suprasert, MD*, Chailert Phongnarisorn, MD*, Sitthicha Siriaree, MD*, Kittipat Charoenkwan, MD*
Affiliation : * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Maharaj Nakorn Chiangmai Hospital, Chiangmai University, Chiang Mai ** Division of Therapeutic Radiology and Oncology, Department of Radiology, Faculty of Medicine, Maharaj Nakorn Chiangmai Hospital, Chiangmai University, Chiang Mai
Objectives : To evaluate the outcomes and adverse effects of concurrent cisplatin -based chemoradiation and
adjuvant hysterectomy for bulky stage IB-IIA cervical cancer.
Materials and Methods : All eligible, thirty-four patients with bulky stage IB-IIA cervical cancer were assigned
to receive weekly cisplatin 40 mg/m 2 for 6 cycles concurrently with radiation followed by extrafascial hyster-
ectomy 6 weeks after completion of radiation.
Results : Estimated 5-year progression-free and disease-free survival rates of 80% were observed after a
median follow-up of 42 months. The overall recurrent rate was 18%. Grade 3 neutropenia and anemia were
noted in only 5.9% and 2.9%, respectively. All acute toxicities were transient and were manageable. There
were no treatment-related deaths or late toxicities.
Conclusion : For appropriately selected patients with bulky stage IB-IIA cervical cancer, concurrent cisplatin-
based chemoradiation followed by adjuvant hysterectomy offers an effective treatment option with acceptable
toxicity.
Keywords : Concurrent chemoradiation, Adjuvant hysterectomy, Stage IB-IIA cervical cancer
